相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation
Takeo K. Maeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in ulcerative colitis
S. Slevin et al.
JOURNAL OF CROHNS & COLITIS (2019)
Selective depletion of LAG3+cells in T-cell-driven inflammation: a randomised, double-blind, placebo-controlled, FTIH phase I/Ib clinical trial
J. Ellis et al.
JOURNAL OF CROHNS & COLITIS (2019)
New emerging targets in cancer immunotherapy: the role of LAG3
Hannah Christina Puhr et al.
ESMO OPEN (2019)
The acidic protein rich in leucines Anp32b is an immunomodulator of inflammation in mice
Jan Chemnitz et al.
SCIENTIFIC REPORTS (2019)
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease A Systematic Review
Noha Abdel-Wahab et al.
ANNALS OF INTERNAL MEDICINE (2018)
P064 Intestinal expression of LAG-3 correlates with inflammatory activity and response to biological therapy in ulcerative colitis
S Slevin et al.
Journal of Crohns & Colitis (2018)
Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction
Bhagyashree Bhagwat et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2018)
LAG3+ Regulatory T Cells Restrain Interleukin-23 Producing CX3CR1+ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis
David Bauche et al.
IMMUNITY (2018)
LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
Takumi Maruhashi et al.
NATURE IMMUNOLOGY (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis
Shinichiro Nakachi et al.
ARTHRITIS RESEARCH & THERAPY (2017)
LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes
Qianxia Zhang et al.
SCIENCE IMMUNOLOGY (2017)
Selective CD28 Antagonist Blunts Memory Immune Responses and Promotes Long-Term Control of Skin Inflammation in Nonhuman Primates
Nicolas Poirier et al.
JOURNAL OF IMMUNOLOGY (2016)
Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies
Alexandra Belson et al.
INFLAMMATION RESEARCH (2016)
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
Katrin Klocke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors
Ameet K. Mishra et al.
ONCOTARGET (2016)
Primate autoimmune disease models; lost for translation?
Bert A. 't Hart
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2016)
T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
Eoin F. McKinney et al.
NATURE (2015)
Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies
Zhijie Jey Cheng et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2014)
Immunogenicity of mAbs in non-human primates during nonclinical safety assessment
Peter J. K. van Meer et al.
MABS (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection
Noah S. Butler et al.
NATURE IMMUNOLOGY (2012)
Development of a Delayed-Type Hypersensitivity (DTH) Model in the Cynomolgus Monkey
Caroline Bouchez et al.
JOURNAL OF TOXICOLOGIC PATHOLOGY (2012)
Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3+)-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates
N. Poirier et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3
Maria Bettini et al.
JOURNAL OF IMMUNOLOGY (2011)
HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression
Bahareh Vali et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells
Yu Liu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
Constantinos Petrovas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Lydie Trautmann et al.
NATURE MEDICINE (2006)
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells
L Maçon-Lemaître et al.
IMMUNOLOGY (2005)
MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223)
S Andreae et al.
BLOOD (2003)
Cutting edge: Molecular analysis of the negative regulatory function of lymphocyte activation gene-3
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2002)
Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223)
S Andreae et al.
JOURNAL OF IMMUNOLOGY (2002)
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3):: role of LAG-3/MHC class II interactions in cell-cell contacts
CE Demeure et al.
EUROPEAN JOURNAL OF CANCER (2001)
分享论文
